[ad_1]
According to reports, Pfizer’s plans to develop an antiviral pill to fight and prevent COVID-19 were rolled out in March 2021 and have been in development mode ever since.
The antiviral pill is planned in a way that could help people avoid their risk of COVID-19 completely, if they come in contact with someone who tests positive for the virus, or who has suspected symptoms of COVID. -19. Antiviral therapy, developed in a way similar to how HIV-AIDS and flu preventive pills work, aims to effectively stop or slow the production of enzymes that facilitate viral growth and reproduction once the virus infects the body. .
The trial will test the safety and effectiveness of the pill with ritonavir, another antiviral widely used to treat HIV. It works in a way that stops the virus in the early stages, so there is a tiny chance that the contagion will spread and cause a potential infection. The medicine is intended to be given at the first sign of infection, just as the virus enters so that there is minimal risk of infection, or if the infection has spread causing serious infection. Thus, it is aimed specifically at people who have been in contact with COVID + people. Apart from that, Pfizer is also conducting another study to see how well the drug might work in those who have already developed an infection.
There are two similar drugs developed by Merck & Co. and Ridgeback Biotherapeutics and Roche and Atea Pharmaceuticals, at different stages of planning.
[ad_2]
Source link